ALT Q2 2022 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$353M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8,000-94.2% YoY

Gross Profit

$8,000100.0% margin

Operating Income

-$20M-254937.5% margin

Net Income

-$20M-251337.5% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-75.0%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$210M

Total Liabilities

$15M

Stockholders' Equity

$195M

Cash & Equivalents

$136M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8,000	$137,000	-94.2%
Gross Profit	$8,000	-$13M	+100.1%
Operating Income	-$20M	-$25M	+18.0%
Net Income	-$20M	-$25M	+19.0%